TherapeuticsMD(TXMD) - 2024 Q4 - Annual Results

Financial Performance - TherapeuticsMD, Inc. announced its financial results for the full year ended December 31, 2024[5] - The company reported a total revenue of $150 million for 2024, representing a 20% increase compared to 2023[5] - Net loss for the year was$ 30 million, a reduction from a net loss of $40 million in 2023, indicating improved financial performance[5] - Future guidance indicates expected revenue growth of 30% for 2025, projecting total revenue of$ 195 million[5] - The company remains committed to maintaining a strong balance sheet with cash reserves of $50 million as of December 31, 2024[5] User Growth - The company achieved a 15% increase in user base, reaching 500,000 active users by the end of 2024[5] Product Development - TherapeuticsMD plans to launch two new products in 2025, aiming to capture additional market share in women's health[5] - The company has invested$ 10 million in R&D for new technologies aimed at improving treatment efficacy[5] Market Expansion - The company is focusing on expanding its market presence in Europe, targeting a 25% growth in that region by the end of 2025[5] - TherapeuticsMD is exploring potential acquisition opportunities to enhance its product portfolio and market reach[5]